Rofecoxib, a non-steroidal anti-inflammatory drug (NSAID), is known to have specific benefits for the stomach lining compared to aspirin. Aspirin, also an NSAID, is known to cause gastrointestinal (GI) side effects, including erosions, ulcers, and bleeding [1].

Rofecoxib, a selective COX-2 inhibitor, has been shown to have a lower incidence of GI side effects compared to aspirin. This is mainly due to its mechanism of action, which specifically inhibits the COX-2 enzyme, involved in inflammation and pain, without affecting the COX-1 enzyme, which plays a crucial role in maintaining the mucosal lining of the stomach [2].

In contrast, aspirin inhibits both COX-1 and COX-2 enzymes, leading to a higher risk of GI side effects [3]. Rofecoxib's selective inhibition of COX-2 results in a reduced risk of GI side effects, making it a more stomach-friendly option compared to aspirin [4].

However, it is important to note that rofecoxib has been associated with an increased risk of cardiovascular events, leading to its withdrawal from the market in 2004 [5]. Therefore, while rofecoxib may offer specific stomach lining benefits over aspirin, its use should be carefully considered and balanced against its potential risks.

Sources:
[1] "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)." Mayo Clinic, Mayo Foundation for Medical Education and Research, 14 Jan. 2021, <https://www.mayoclinic.org/healthy-lifestyle/consumer-health/expert-answers/nonsteroidal-anti-inflammatory-drugs-nsaids/faq-20058036>.
[2] "Rofecoxib." MedlinePlus, U.S. National Library of Medicine, <https://medlineplus.gov/druginfo/meds/a602002.html>.
[3] "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)." American College of Gastroenterology, <https://gi.org/topics/nonsteroidal-anti-inflammatory-drugs-nsaids/>.
[4] "Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Peptic Ulcers." National Institute for Health and Care Excellence (NICE), 19 Mar. 2015, <https://www.nice.org.uk/guidance/cg177/chapter/1-Guidance>.
[5] "Rofecoxib (Vioxx)." DrugPatentWatch, <https://drugpatentwatch.com/drugs/rofecoxib>.